An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant.
PSP
agrammatism
aphasia
apraxia of speech
midbrain
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
19
04
2019
accepted:
12
05
2019
entrez:
9
8
2019
pubmed:
9
8
2019
medline:
9
8
2019
Statut:
epublish
Résumé
The Movement Disorder Society clinical criteria for progressive supranuclear palsy (PSP) provide a framework for assessing the presence/severity of clinical symptoms and define a speech/language variant of PSP. To evaluate the clinical criteria in a cohort of speech/language patients with longitudinal follow-up. A total of 52 patients presenting with progressive apraxia of speech and/or agrammatic aphasia were followed longitudinally for up to 6 visits with clinical assessments and magnetic resonance imaging. We assessed oculomotor, postural instability, and akinesia diagnostic levels and determined whether patients met criteria for possible PSP-speech/language or probable PSP at each visit. Kaplan-Meier curves assessed time-to-event probabilities according to age. Statistical parametric mapping and midbrain volume were assessed according to disease progression. Few PSP symptoms were observed early in the disease, with oculomotor abnormalities and falls first observed 2 years after onset. Falls were more common than vertical supranuclear gaze palsy. Bradykinesia and rigidity commonly developed but axial was rarely greater than appendicular rigidity. During follow-up, 54% met criteria for possible PSP-speech/language, 38% for probable PSP-Richardson's syndrome, and 38% for probable PSP-parkinsonism, most commonly 6 to 6.9 years after onset. The probability of developing PSP was greater when onset was at an age older than 70 years. Patients who progressed to probable PSP had more parkinsonism and oculomotor impairment at baseline and greater midbrain atrophy when compared with those who did not develop probable PSP. Symptoms typical of PSP commonly develop in patients presenting with a progressive speech/language disorder. Older age appears to be an important prognostic factor in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
The Movement Disorder Society clinical criteria for progressive supranuclear palsy (PSP) provide a framework for assessing the presence/severity of clinical symptoms and define a speech/language variant of PSP.
OBJECTIVES
OBJECTIVE
To evaluate the clinical criteria in a cohort of speech/language patients with longitudinal follow-up.
METHODS
METHODS
A total of 52 patients presenting with progressive apraxia of speech and/or agrammatic aphasia were followed longitudinally for up to 6 visits with clinical assessments and magnetic resonance imaging. We assessed oculomotor, postural instability, and akinesia diagnostic levels and determined whether patients met criteria for possible PSP-speech/language or probable PSP at each visit. Kaplan-Meier curves assessed time-to-event probabilities according to age. Statistical parametric mapping and midbrain volume were assessed according to disease progression.
RESULTS
RESULTS
Few PSP symptoms were observed early in the disease, with oculomotor abnormalities and falls first observed 2 years after onset. Falls were more common than vertical supranuclear gaze palsy. Bradykinesia and rigidity commonly developed but axial was rarely greater than appendicular rigidity. During follow-up, 54% met criteria for possible PSP-speech/language, 38% for probable PSP-Richardson's syndrome, and 38% for probable PSP-parkinsonism, most commonly 6 to 6.9 years after onset. The probability of developing PSP was greater when onset was at an age older than 70 years. Patients who progressed to probable PSP had more parkinsonism and oculomotor impairment at baseline and greater midbrain atrophy when compared with those who did not develop probable PSP.
CONCLUSIONS
CONCLUSIONS
Symptoms typical of PSP commonly develop in patients presenting with a progressive speech/language disorder. Older age appears to be an important prognostic factor in these patients.
Identifiants
pubmed: 31392246
doi: 10.1002/mdc3.12796
pii: MDC312796
pmc: PMC6660227
doi:
Types de publication
Journal Article
Langues
eng
Pagination
452-461Subventions
Organisme : NIDCD NIH HHS
ID : R01 DC010367
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC012519
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS089757
Pays : United States
Références
Neuroimage. 2000 Jun;11(6 Pt 1):805-21
pubmed: 10860804
Brain. 2005 Jun;128(Pt 6):1247-58
pubmed: 15788542
Neuroimage. 2005 Jul 1;26(3):839-51
pubmed: 15955494
Neurocase. 2005 Aug;11(4):283-96
pubmed: 16093229
Brain. 2006 Jun;129(Pt 6):1385-98
pubmed: 16613895
Brain. 2007 Jun;130(Pt 6):1552-65
pubmed: 17405767
Mov Disord. 2007 Nov 15;22(15):2235-41
pubmed: 17712855
Handb Clin Neurol. 2008;89:487-91
pubmed: 18631771
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Neurology. 2010 Jan 5;74(1):42-9
pubmed: 19940270
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Arch Neurol. 2011 Jun;68(6):753-60
pubmed: 21670399
Neurocase. 2012;18(6):478-88
pubmed: 22181323
Brain. 2012 May;135(Pt 5):1522-36
pubmed: 22382356
Eur J Neurol. 2013 Apr;20(4):629-37
pubmed: 23078273
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
Neurology. 2013 Jul 23;81(4):337-45
pubmed: 23803320
Parkinsonism Relat Disord. 2014 Feb;20(2):180-5
pubmed: 24252300
Brain. 2014 Oct;137(Pt 10):2783-95
pubmed: 25113789
J Neurol. 2015 Mar;262(3):783-8
pubmed: 25701010
Cortex. 2015 Aug;69:220-36
pubmed: 26103600
JAMA Neurol. 2016 Jun 1;73(6):733-42
pubmed: 27111692
Ann Neurol. 2017 Mar;81(3):430-443
pubmed: 28133816
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neurology. 2017 Nov 28;89(22):2271-2279
pubmed: 29093069
Neurocase. 2018 Apr;24(2):111-120
pubmed: 29799310
Expert Rev Neurother. 2018 Jul;18(7):603-616
pubmed: 29902389
Mov Disord. 2019 Mar 18;:null
pubmed: 30884545
Brain. 2019 Aug 1;142(8):2466-2482
pubmed: 31199471